Stock INBX INHIBRX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Inhibrx, Inc.

Equities

INBX

US45720L1070

Real-time Estimate Cboe BZX
Other stock markets
 11:07:42 2024-05-10 EDT 		5-day change 1st Jan Change
34.67 USD -0.06% Intraday chart for Inhibrx, Inc. +1.67% -8.63%
02-28 Inhibrx Shares Fall After Q4 Net Loss Widens MT
02-28 Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibrx : Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Form 8-K
PU
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
BU
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
PR
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
PR
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
PR
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
BU
Sanofi bets $1.7b on potential best-in-class rare disease therapy
AQ
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
AQ
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
PR
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
BU
Mintz Launches Podcast Series On Women Leaders In Health Care
AQ
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
PR
Inhibrx Announces Participation in Upcoming Scientific Conferences
PR
Inhibrx : Poster Presentation
PU
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
AQ
Inhibrx Announces $200 Million Private Placement Financing
PR
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
PR
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
PR
INHIBRX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Inhibrx : EPoster
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INBX Stock
  4. News Inhibrx, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW